5 EASY FACTS ABOUT CLINICAL BREAST CANCER DESCRIBED

Genomic sequencing Assessment of 733 HER2-amplified Most important and metastatic breast tumours disclosed considerable enrichment of mutations that activate RAS–MAPK signalling in Superior tumours addressed with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, lead to resistance to tucatinib and ner